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Abstract
Background: The promotility agents currently available to treat gastroparesis and feed intolerance in the critically ill
are limited by adverse effects. The aim of this study was to assess the pharmacodynamic effects and pharmacokinetics
of single doses of the novel gastric promotility agent motilin agonist camicinal (GSK962040) in critically ill feed-
intolerant patients.
Methods: A prospective, randomized, double-blind, parallel-group, placebo-controlled, study was performed in
mechanically ventilated feed-intolerant patients [median age 55 (19–84), 73 % male, APACHE II score 18 (5–37) with
a gastric residual volume ≥200 mL]. Gastric emptying and glucose absorption were measured both pre- and post-
treatment after intragastric administration of 50 mg (n = 15) camicinal and placebo (n = 8) using the 13C-octanoic acid
breath test (BTt1/2), acetaminophen concentrations, and 3-O-methyl glucose concentrations respectively.
Results: Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric
means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and
increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs. post-treatment: 71.63 mmol.min/L; 95 %
CI (1.68, 3.72)]. When two patients who did not have detectable plasma concentrations of camicinal were excluded
from analysis, camicinal accelerated gastric emptying (adjusted geometric means: pre-treatment BTt1/2 121 minutes vs.
post-treatment 65 minutes 95 % CI (0.32, 0.91) and increased glucose absorption (AUC240min pre-treatment: 33.
04 mmol.min/L vs. post-treatment: 74.59 mmol.min/L; 95 % CI (1.478, 3.449). In those patients receiving placebo gastric
emptying was similar pre- and post-treatment.
Conclusions: When absorbed, a single enteral dose of camicinal (50 mg) accelerates gastric emptying and increases
glucose absorption in feed-intolerant critically ill patients.
Trial registration: The study protocol was registered with the US NIH clinicaltrials.gov on 23 December 2009
(Identifier NCT01039805).
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Background
Enteral nutrient delivery is frequently inadequate in the
critically ill [1]. Poor nutrition results in impaired
immune function, prolonged ventilator dependence,
increased infectious complications, and overall poorer
outcomes when compared to those that receive adequate
nutrition [2]. Gastric emptying (GE) is slowed in up to
50–60 % of mechanically ventilated patients, resulting in
an inability to deliver adequate nutrition by the gastric
route [3]. This is manifest as increased gastric residual
volumes (GRV), or regurgitation and vomiting, which
can lead to aspiration of gastric contents, resulting in
respiratory compromise and ventilator-associated pneu-
monia [3].
Enhancing gastric emptying by the administration of
gastrokinetic agents is a recommended strategy for
optimizing delivery and minimizing the risks of enteral
nutrition (EN) [4]. Gastrokinetic drugs such as erythro-
mycin and metoclopramide have been shown to acutely
accelerate GE, reduce GRVs, and increase delivery of
calories via the gastric route [5–12].
Metoclopramide is an antagonist of central and
peripheral dopamine receptors and has been reported to
be somewhat useful as a gastrokinetic drug [7], although
less effective than erythromycin [10–12]. Concerns
regarding extrapyramidal side effects have also been
reported [13]. Erythromycin is a macrolide antibiotic
and motilin receptor agonist, and while it is a potent
gastrokinetic drug, there is the potential risk of QT pro-
longation and cardiac arrhythmias [14]. Additionally,
there is concern that widespread use of this antibiotic in
non-infected patients could promote the development of
microbial resistance [14]. Furthermore, there is a marked
and rapid tolerance to the gastrokinetic effects of both
metoclopramide and erythromycin in critically ill pa-
tients [11]. Safer more effective gastrokinetic agents that
have a sustained effect could improve nutrient delivery
and thereby clinical outcomes in patients with critical
illness.
Motilin is an endogenous peptide, produced mainly in
the duodenum, whose physiological action is mediated
by motilin receptors located on enteric neurons and on
the smooth muscle of the gut. Endogenous motilin is
responsible for the initiation of phase III contractions of
the migrating motor complex (MMC) [15], which is
thought to perform a “housekeeping role” by clearing
the stomach and intestine of luminal secretions, un-
digested material and bacteria during the interdigestive
period. Administration of exogenous drugs that stimu-
late motilin receptors accelerate gastric emptying [16].
Camicinal (GSK962040) is a first-in-class small mol-
ecule (non-macrolide) motilin receptor agonist with the
potential to accelerate gastric emptying [17, 18]. Camic-
inal was designed to enhance the specificity for the
recombinant human motilin receptor and potentially
decrease the negative characteristics encountered with
compounds with complex and nonspecific motilide
structures. Camicinal has been shown to accelerate gas-
tric emptying by 30–40 % in healthy volunteers as single
(50–150 mg) or 14-day repeat oral doses (50–125 mg)
[19, 20]. Similarly, in patients with type 1 diabetes and
gastroparesis, camicinal accelerated gastric emptying by
35–60 % [21].
Enhancing GE in critically ill patients receiving EN
may improve the delivery of nutrition and thereby im-
prove nutritional and clinical outcomes. The objectives
of this study were to assess the effects of single doses of
camicinal on gastric emptying, by the 13C-octanoic acid
breath test, acetaminophen absorption test, and glucose
absorption by 3-O-methyl glucose (3-OMG) in critically
ill patients who were “intolerant” to enteral feeding.
Methods
The study was conducted in the intensive care unit
(ICU) at the Royal Adelaide Hospital in Adelaide, South
Australia, which is a mixed tertiary referral unit with a
university affiliation. The study was run in accordance
with “good clinical practice” (GCP), the Declaration of
Helsinki and the National Health and Medical Research
Council of Australia guidelines on research conducted
on unconscious patients after obtaining informed
consent from each patient’s next of kin. The study was
approved by the Royal Adelaide Hospital Research Ethics
Committee (Approval Number: 090924). The study
protocol (GSK number 112571) was registered with
the US NIH clinicaltrials.gov on 23 December 2009
(Identifier NCT01039805).
Patients
Eligible patients were males and females between 18 and
85 years of age, undergoing invasive mechanical ventila-
tion in the ICU who developed “feed intolerance” during
nasogastric feeding. Patients were fed according to the
Royal Adelaide Hospital feeding protocol, which is to
commence 1 kcal/mL standard liquid nutrient feed at
goal rate (to a maximum of 80 mL/h) [21], unless there
are contraindications to enteral feed and to check GRVs
every 6 hours [14]. “Feed intolerance” was defined as a
single GRV ≥ 200 mL occurring at least 6 hours after
commencing liquid nutrient at ≥ 40 kcal/hr [22]. Patients
were expected to remain mechanically ventilated for at
least 48 hours after enrollment and expected to survive
for at least 24 hours after dosing of study medication.
Additional inclusion criteria included the following: body
weight ≥ 50 kg, average QTcB or QTcF < 450 msec; or
QTc < 480 msec in subjects with bundle branch block,
aspartate aminotransferase and alanine transaminase < 3
times the upper limit of normal; alkaline phosphatase
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and bilirubin ≤ twice the upper limit of normal. Patients
were excluded if there was a known history of hepatitis
B, C or HIV, they had received a drug known to have
gastrokinetic effects in the previous 24 hours (e.g.,
erythromycin, azithromycin or metoclopramide), they
had mechanical bowel obstruction, they were pregnant
or lactating women, the investigator did not think they
would be able to complete the study, they had a current
or chronic history of liver disease, or known hepatic or
biliary abnormalities (with the exception of Gilbert’s
syndrome or asymptomatic gallstones), they had partici-
pated in a clinical trial and had received an investiga-
tional product within the following time period prior to
the first dosing day in the current study: 30 days, five
half-lives or twice the duration of the biological effect of
the investigational product (whichever is longer), they
were receiving or likely to receive drugs known to in-
hibit or induce CYP3A4 within the restricted timeframe
relative to dosing of study medication, they had renal
failure requiring replacement therapy (dialysis or filtra-
tion), the reason for admission to ICU was an overdose
(deliberate or accidental; medicinal product or not), they
had altered upper gastrointestinal tract anatomy, they
had undergone upper gastrointestinal tract surgery on
this admission to ICU, they had a gastric pacemaker,
were receiving parenteral feeding, had sensitivity to any
of the study medications, or components thereof.
All patients had a feeding tube in situ with the distal
tip either 10 cm below the gastro-esophageal junction or
clearly visualized in the stomach on plain abdominal
radiograph.
Study design
This trial was designed as a randomized, double-blind,
parallel, single-dose, placebo-controlled study. It en-
rolled two cohorts of subjects. In the initial cohort,
eligible patients were randomized in a ratio of 1:2 to
receive a single dose of either placebo (n = 8) or
50 mg of camicinal (n = 15) in accordance with the
randomization schedule generated by Discovery Bio-
metrics GSK (GlaxoSmithKline, Harlow, UK), prior to
the start of the study, using the validated internal
software RandAll. Research staff accessed a web-based
program to determine the allocation of each patient
following consent. Hence allocation concealment was
maintained. All patients, clinical and research staff at
the site were blinded to the intervention. The dose of
50 mg was chosen as this dose had a proven gastroki-
netic effect in healthy participants and was at the
lower end of doses administered [19]. Because of the
capacity for critically ill patients to have slow gastric
emptying and a larger volume of distribution [23], a
preplanned interim analysis of safety and pharmaco-
kinetics (with investigators remaining blinded to
pharmacodynamics) was performed and if the enteral
dose of 50 mg appeared safe, but plasma concentra-
tions of camicinal were not in the pharmacology
range expected, the dose was increased and a second
cohort of subjects received either placebo (n = 4) or
75 mg of camicinal (n = 6) to explore the pharmaco-
dynamic effects of an increased dose.
Once enrolled, each subject completed “baseline”’
(pre-treatment) assessments of GE by 13C-octanoic acid
breath test, acetaminophen absorption test, and glucose
absorption test following 3-O-methyl glucose adminis-
tration. Following the completion of the 4-hour gastric
emptying measurement the patient was commenced on
nutrient infusion at the rate they had been receiving
prior to enrollment. On the following day after a 2-hour
fast, study treatment was administered into the stomach
via the NG tube as a 20-mL suspension in 90 mL of
water or 110 mL of water at T = −90 min. Gastric
emptying measurements were repeated 90 minutes
after administration of randomized study treatment
(i.e., T = 0 min). Subject safety was monitored via
clinical observations, heart rate, and blood pressure
measurements, electrocardiogram tracings and clinical
laboratory determinations conducted from baseline to
5 days post-dose. A final follow-up evaluation was
conducted between 7 and 10 days post-dose.
Test meal
Patients were studied in the supine position and the
head of the bed was elevated to 30 °. Gastric contents
were initially aspirated and discarded, and then 100 mL
of liquid nutrient meal (Ensure; Abbott Australia, Mac-
quarie Park, NSW, Australia), providing 106 kcal with
21 % of fat, was infused into the stomach over 5 minutes.
The 100 mL feed included 100 mg of 13C-octanoate
(100 mg/mL; Cambridge Isotope Laboratories, Inc.,
Andover, MA, USA), 1000 mg acetaminophen solution
(Panadol™ syrup; GlaxoSmithKline, Ermington, NSW,
Australia) and 3 g 3-O-methyl glucose (3-OMG;
Sigma-Aldrich, Castle Hill, NSW, Australia). Time = 0
mins was defined as the time when all of the 100 mL
of feed was infused into the stomach.
13C-octanoic acid breath test
End-expiratory breath samples were obtained as previ-
ously described [24]. Samples were collected at baseline,
every 5 minutes for the first hour, and every 15 minutes
thereafter, for the subsequent 3 hours after meal admin-
istration. Breath samples were analyzed for CO2 concen-
tration and the percentage of 13CO2 using an isotope
ratio mass spectrometer (ABCA model 20 20, Europa
Scientific, Crewe, UK). The values obtained were used to
determine the percentage of 13C recovered per hour,
which was plotted over time. These data were used to
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2403 patients were admitted to the 
Intensive Care Unit between 
January 2010 and June 2011
16 patients were randomized 
to 50mg Camicinal
6 patient’s surrogate decision maker
declined consent
502 patients anticipated to be 
mechanically ventilated for >48 h 
and receiving >40ml/hr EN were 
assessed for eligibility
1901 patients were not mechanically 
ventilated / expected to be mechanically 
ventilated for < 48 h or were not receiving 
>40ml/hr EN
298 mechanically ventilated patients 
receiving >40ml/hr EN had a GRV < 
200ml
4 patients were excluded after consent
1 Feeding tube found to be in the 
duodenum
1 Found to be infected with Hepatitis C
1 Required active treatment for feed 
intolerance 
1 Elevated LFTs prior to dosing
34 patients underwent 
randomization
6 patients were randomized 
to 75mg Camicinal






12 patients received placebo























Deranged liver function 
Not expected to remain mechanically 
ventilated for at least 48 hours after 
enrolment
Use of drug known to have 
gastrokinetic effects
Prolonged QTc
Not expected to complete study
Surrogate decision marker not 
available
Admitted with bowel obstruction or 
perforation.
Renal failure
<18 or >85 years of age
Infected with Hepatitis B, Hepatitis C, 
or HIV viruses
Recent enrolment in another clinical 
trial
Altered upper GI tract or surgery this 
admission
Pregnancy/lactation
Admitted with drug overdose
Unable to be fed according to study 
protocol 
Receiving parenteral nutrition
Small intestinal feeding tube inserted 
for clinical reasons
204 mechanically ventilated patients 
200ml
44 patients were eligible for consent
38 patient’s surrogate decision 
maker consented
Fig. 1 (See legend on next page.)
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calculate the best fit curves for percent dose per hour
and percent cumulative dose [9, 12]. From the resultant
curves, the gastric half-emptying time (BTt½) was de-
rived using the following formula [9, 12]: BTt½ = [−1/k] ×
ln[1 – 2-1/b]. The area under the recovery curve was
used to calculate (i) gastric half-emptying time (BTt½),
which is the time to 50 % of the total 13C recovered
and (ii) the gastric emptying coefficient (GEC) as a glo-
bal index for the gastric emptying rate (which accounts
for the rate of appearance and disappearance of tracer
in the breath) with the greater the number indicating
the more rapid the emptying rate.
Blood samples
Blood samples were collected in chilled ethylenediamine-
tetraacetic acid (EDTA) tubes and separated within 30 mi-
nutes of collection for assessment of camicinal and
acetaminophen concentrations. Blood was also collected
into serum tubes for subsequent measurement of 3-OMG
concentrations. Both serum and plasma were separated by
centrifugation (3200 rpm for 15 minutes at 4 °C). Samples
were then stored at −80 °C until assayed [25].
Glucose absorption (serum 3-O-methly glucose
concentrations)
Glucose absorption was measured using 3-OMG, a pre-
viously validated technique in the critically ill [22, 26].
Arterial blood samples (5 mL) for plasma 3-OMG
concentration were collected at baseline, 15, 30, 45, 60,
90, 120, and 240 minutes post-3-OMG dose for analysis
by high-performance exchange chromatography. Peak 3-
OMG concentration (Cmax), time to peak 3-OMG con-
centration (Tmax) and area under the curve between
the end of the meal (T = 0) and 240 mins (AUC0–240)
were calculated.
Plasma acetaminophen concentrations
Blood (5 mL) was obtained for measurement of plasma
acetaminophen concentrations at 90, 60, and 30 minutes
before the meal and 15, 30, 45, 60, 120 and 240 minutes
after the meal, following acetaminophen dosing. Samples
were analyzed by protein precipitation followed by liquid
chromatography-tandem mass spectrometry (LC-MS/
MS) analysis with a method range of 25–5000 ng/mL,
using a 50 μL aliquot of human plasma. The concentra-
tion at 60 minutes after the end of the meal (C60) and
area under the curve between the end of the meal (T = 0)
and 60 minutes (AUC0–60) were calculated.
Plasma camicinal concentrations
Plasma camicinal concentrations were measured 90,
60, and 30 minutes before the meal and 15, 30, 45,
60, 120 and 240 minutes after the meal. Samples were
analyzed using a validated HPLC with a method range
1 to 2000 ng/mL.
Data analysis
Demographics
Sample size was estimated using data from a previous
study where gastric emptying was measured using the
13C-octanoic acid breath test in an unselected group of
30 critically ill patients (BTt½ placebo mean estimate:
132.33 min, within-subject SD: 27.68 min) [27]. Based
on these data it was estimated that a sample size of 12
would give 88 % power to detect a 30 % decrease of
BTt½ (using a two-sided α = 0.05 level) between pre-
and post-dose within each treatment group. Additional
subjects were recruited because of expected dropouts
between day 1 and day 2.
In this proof-of-principal study the acute effects of
camicinal administered intragastrically were studied.
Because absolute gastroparesis occurs in a proportion of
critically ill patients [14, 28], it was anticipated that an
enterally delivered drug may not empty adequately from
the stomach and, therefore, would not be absorbed in
patients with severe gastroparesis. For this reason it was
decided to carry out an exploratory analysis in addition
to the primary analysis in patients that achieved evalu-
able plasma camicinal concentrations.
Pharmacodynamics
Pharmacodynamic parameters were analyzed using a
mixed model fitting treatment, visit (baseline or “pre-
treatment”, and posttreatment) and the interaction as
fixed effects and subject as random. For each treatment,
the point estimate and corresponding 95 % confidence
interval for the difference “posttreatment – baseline”
was constructed, using the residual error from the
model. Where applicable, the log-transformed parame-
ters were back transformed. If the confidence interval
did not include zero (or one for log-transformed parame-
ters), the difference was considered nominally significant
at the 5 % level (unadjusted for multiple comparisons).
All statistical analyses were carried out using SAS v. 9.2
(SAS Institute, Cary, NC, USA).
(See figure on previous page.)
Fig. 1 Consort diagram. Next of kin consent was provided for six patients who subsequently did not receive study drug because of the following:
feeding tube found to be in the duodenum, found to be hepatitis C positive after consent given, consent given and subsequently withdrawn,
patient withdrawn by investigator (not in best interest of patient to continue), liver function tests elevated meeting exclusion criteria, patient died
after consent given but prior to receiving study treatment. EN enteral nutrition, GRV gastric residual volumes
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Pharmacokinetics
Plasma pharmacokinetic parameters for camicinal were
derived using Phoenix WinNonlin v. 6.2 (Certara,
Princeton, NJ, USA) from dried blood spot concentra-
tions and are summarized as geometric means and
coefficient of variation (CVb%) or median and range.
Acetaminophen and 3-OMG plasma pharmacokinetic
parameters were derived using Phoenix WinNonlin v.
6.2 from plasma concentrations and are summarized
in Table 3 and 4.
Safety
An adverse event (AE) was defined as any untoward
medical occurrence or unfavorable and unintended sign
including an abnormal laboratory finding), symptom, or
disease (new or exacerbated) temporally associated with
the use of the study medication. Events that met the
definition of an AE included: any abnormal laboratory
test results (hematology, clinical chemistry, or urinalysis)
or other safety assessments (e.g., ECGs, radiological
scans, vital signs measurements), including those that
worsen from baseline, and felt to be clinically significant
in the medical and scientific judgment of the invest-
igator, exacerbation of a chronic or intermittent pre-
existing condition including either an increase in fre-
quency and/or intensity of the condition, new conditions
detected or diagnosed after study medication administra-
tion even though it may have been present prior to the
start of the study, and/or signs, symptoms, or the clinical
sequelae of a suspected interaction.
Using clinical judgment, the investigator assessed
the relationship between study medication and the
occurrence of each AE/serious adverse event (SAE) to
determine study drug-related AEs.
Results
Between January 2010 and June 2011, 204 patients were
screened (Fig. 1). A total of 33 patients were randomized
into the study with similar demographics across the
treatment groups (Table 1).
Plasma camicinal
Following intragastric administration, camicinal concen-
trations (AUC0-24h; geometric mean (%CV)) were 5205.9
(151.0) and 13,245.9 (42.0) ng.h/mL following 50 and
75 mg doses, respectively, with median Tmax 1.5 h
(range 0.25, 7.5 h) and 1.25 (min: 1, max: 3 h). In two
patients receiving 50 mg, plasma camicinal exposures
did not increase within the pharmacodynamic evaluation
period (the first 240 minutes post meal) with Tmax
occurring in these subjects at 3 and 7.5 h, respectively.
In the 50 mg group, analyses were performed as
“intention to treat”, which included all patients (n = 15),
and a “modified per protocol analysis” including only
Table 1 Patient demographics
Camicinal
Placebo 50 mg 75 mg
N = 12 N = 15 N = 6
Age in years, mean (SD) 46 (17) 63 (17) 42 (14)
Sex, n (%)
Female: 2 (17) 6 (40) 1 (16)
Male: 10 (83) 9 (60) 5 (83)
BMI (kg/m2), mean (SD) 28.8 (5.8) 29.0(6.2) 28.7 (3.7)
Height (cm), mean (SD) 173 (8) 172 (10) 178 (9)




73.1 (33) 89.3 (84) 56.0 (7.3)
Baseline hepatic function
ALT (IU/L), mean (SD) 44.6 (30) 34.7 (22) 58.3 (39)
AST (IU/L), mean (SD) 43.2 (23) 35.6 (19) 55.2 (39)
Total bilirubin (μmol/L),
mean (SD)
10.5 (15) 10.2 (13) 5.7 (3.7)
Admission category, n (%)
Trauma 5 (42) 4 (27) 1 (17)
Head injury 1 (8) 3 (20) 1 (17)
Respiratory failure 1 (8) 3 (20) 0
Sepsis 2 (17) 2 (13) 0
Other 3 (25) 3 (20) 4 (67)
Illness severity and duration
APACHE II, median (min, max) 17.5 (6, 37) 19 (5, 30) 14 (7, 29)
Days in ICU prior to enrollment,
median (min, max)
4 (1, 9) 4 (2, 19) 4.5 (1, 7)
Days in ICU prior to study,
median (min, max)
5 (2, 10) 5.5 (2, 9) 5 (2, 19)
Days in hospital prior to
study, median (min, max)
5 (2, 10) 7 (3, 26) 5.5 (3, 9)
Concomitant chronic illnesses, n
Diabetes 3 0 0
Concomitant medications, n
Catecholamines 2 6 1
Opioids/opiates 12 14 4
Muscle relaxant 3 3 0
EN prior to enrollment




29 (3, 162) 55 (5, 396) 50 (8, 81)
EN administered (EN delivered
– discarded) in 24 hours prior








SD standard deviation, BMI body mass index, ALT alanine transaminase, AST
aspartate transaminase, APACHE II, Acute Physiologic Assessment and Chronic
Health Evaluation II, ICU intensive care unit, EN enteral nutrition
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those patients in whom the drug was emptied from the
stomach and absorbed, thereby, resulting in detectable
plasma concentrations of camicinal (n = 13).
13C-octanoic acid breath test
Pretreatment (baseline) gastric emptying was not similar
across the different treatment groups. The pretreatment
gastric emptying was slowest in the patients that subse-
quently received 50 mg and fastest in the patients that
subsequently received 75 mg camicinal. The baseline
geometric mean values for BTt½ were 56.87 (80.01 %
between subject CV), 116.98 (98.37 % between subject
CV), and 45.79 (77.48 % between subject CV) minutes
for placebo, 50 mg and 75 mg camicinal, respectively.
While placebo and 75 mg of camicinal had no effect on
gastric emptying compared to baseline there was a
strong trend to accelerated gastric emptying following
the administration of 50 mg camicinal (Table 2). When
analyzing data only from patients who achieved evalu-
able camicinal plasma levels during the GE assessment
period, the acceleration of gastric emptying was more
prominent (Table 2). Of the two patients who did not
appear to absorb the drug during the period when
gastric emptying was assessed (both received 50 mg
camicinal), one had a fourfold increase in BTt½ from
baseline (138.5 min to 585.1 min), indicating slowing
of GE on the day the drug was administered and the
other subject had no change from baseline (63.8 min
to 68.8 min).
Glucose absorption (3-OMG concentrations)
Pretreatment absorption was greater at baseline in both
the placebo and the 75 mg arms compared to the
50 mg group. Camicinal 50 mg substantially increased
glucose absorption in the first hour and for four hours
after the meal (Fig. 2, Table 3).
Plasma acetaminophen
There was a trend for the absorption, as demonstrated
by increased exposure, of acetaminophen to increase
after dosing with 50 mg dose (Table 4) compared to its
absorption at baseline.
Safety
The frequency of reported AEs was similar across both
doses of camicinal and placebo (Table 5). Serious
adverse events (SAE) were reported for three subjects.
There were two fatal SAEs, one event of severe sepsis
and one event of brain herniation, both in the 50 mg
arm. One subject in the placebo arm experienced nonfa-
tal cardiac arrest. None of the SAEs were assessed as
related to study treatment. The effect of camicinal on
QTc was measured and no effect was found.
Discussion
The objectives of this study were to evaluate the
acute effects of camicinal in critically ill patients who
were intolerant of EN. The most important findings
from this study were that, when absorbed, a single
dose of 50 mg camicinal accelerated gastric emptying
and increased glucose absorption in patients with slow
gastric emptying at baseline. In addition, while the drug
was administered enterally, plasma concentrations reflect-
ing pharmacological dosing occurred in the majority of
patients. Adverse events were similar across all treatment
arms.
Camicinal was designed using the recombinant human
motilin receptor to enhance the specificity for the recep-
tor and potentially decrease the negative characteristics
encountered with compounds comprised of complex
and nonspecific motilide structures [18]. This is the first
study in which camicinal was administered to critically
ill subjects with enteral feed intolerance.
Gastric delivery of enteral nutrition is frequently
limited in the critically ill by slow gastric emptying,
Table 2 Gastric emptying measured by 13C-octanoic acid breath test: baseline vs. post study drug comparison
13C-octanoic acid breath test parameters Comparison Baseline (mean) Post study drug (mean) Point estimate 95 % CI
BTt½ (min)* 50 mg (n = 15) 117 76 0.65 (0.39, 1.08)
50 mg (n = 13)# 121 65 0.54 (0.32, 0.91)
75 mg (n = 6) 46 85 1.85 (0.82, 4.15)
Placebo (n = 12) 57 69 1.21 (0.68, 2.15)
GEC 50 mg (n = 15) 2.51 2.82 0.31 (−0.16, 0.77)
50 mg (n = 13)# 2.51 3.05 0.55 (0.09, 1.00)
75 mg (n = 6) 3.09 2.60 −0.49 (−1.23, 0.25)
Placebo (n = 12) 2.90 2.83 −0.06 (−0.58, 0.46)
Least squares means and point estimates are geometric least squares means and ratios for log-transformed parameters. #Two subjects administered 50 mg camicinal
had low drug exposure. Analyses were performed with and without these subjects
BTt½ breath test gastric time to half emptying, GEC gastric emptying coefficient
*Log-transformed
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which occurs in up to 30–50 % of mechanically venti-
lated patients [3, 29]. This is commonly treated with
gastrokinetic agents, the aim of which are to accelerate
delivery of nutrients to the small intestine and augment
nutrient absorption, thereby, improving nutritional and
clinical outcomes. The gastrokinetic agents currently
used are limited by side effects and are also subject to
rapid tachyphylaxis [3, 30]. New drugs that persistently
accelerate gastric emptying and have adequate safety
profiles are needed for the treatment of slow gastric
emptying in critical illness. This study shows that camic-
inal accelerates gastric emptying and that this results in
augmented glucose absorption. Studies to evaluate the
effects of multiple doses of camicinal in the critically
ill are now warranted. Additional studies looking for
a sustained effect on calorie delivery are also needed.
This is the first study to demonstrate that gastric
emptying, when accelerated by a gastrokinetic drug, in-
creases nutrient absorption. This is a predictable result
as it has been previously demonstrated that there is a
strong association between GE and glucose absorption
in critical illness [31]. However, small intestinal absorp-
tion of both glucose and fat is impaired in critical illness
independent of the rate of gastric emptying [32, 33], so
the quantification of improvement in absorption follow-
ing gastric acceleration is important. This study demon-
strated that glucose absorption increased more than
twofold following administration of 50 mg of camicinal,
which is a magnitude of effect that has the capacity to
be clinically relevant [32]. It has been previously demon-
strated that erythromycin increases the absorption of
glucose when nutrient is delivered into the small intes-
tine but fat absorption may be reduced [22]. Octanoic
acid, a medium-chain fatty acid, also showed augmented
absorption when camicinal was administered. Further
study on the effect of gastrokinetic drugs on nutrient
absorption and clinical outcomes is warranted.
At present camicinal is only available as an enteral
formulation. As gastric emptying can be substantially de-
layed in feed-intolerant critically ill patients [14], it was
anticipated that emptying rates in some patients would
be so slow that small intestinal absorption would be neg-
ligible in the acute period after a single dose. However,
pharmacokinetic data indicate that, when gastric empty-
ing occurred, mean concentrations of camicinal were
comparable to healthy subjects and patients with dia-
betic gastroparesis [21]. This suggests that small intes-
tinal absorption of the drug is unaffected by critical
illness in most patients. We speculate that over an
extended period of dosing some emptying would occur,
even in patients with gastric stasis, which would allow
subsequent doses of the drug to be absorbed more
rapidly and allow for the pharmacologic effect to further
enhance gastric emptying. Accordingly, a repeated dose
study is warranted.
Three methods to evaluate gastric emptying were used
in this study. All are indirect techniques that make use
of a marker that is impermeable to gastric mucosa but is
freely absorbed from the small intestine [24]. Each of the
tests has advantages and limitations but the measure-
ment of 13C-octanoic acid breath test, 3-OMG, and acet-
aminophen tests, which quantify lipid, glucose, and drug
absorption respectively, is a strength of this study [28].
Fig. 2 3-OMG (mean ± SEM) plasma concentrations vs. time in the
placebo and 50 mg dose groups. 3-OMG 3-O-methyl glucose
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All demonstrated acceleration in gastric emptying
following the absorption of 50 mg of camicinal although
this was more marked using 3-OMG and the breath test.
Acetaminophen absorption is a difficult test to interpret
in the critically ill given the need to use acetaminophen
for clinical purposes as well as variations in first pass
effects due to hepatic metabolism. Differences in fat and
glucose absorption may also account for some of the
difference in results between 3-OMG and the 13C-octa-
noic acid breath test [22, 34].
Camicinal 50 mg, but not 75 mg, accelerated gastric
emptying in the critically ill. The lack of effect observed fol-
lowing 75 mg may be due to a combination of the small
sample size studied following this dose and the more nor-
mal (rather than slow) gastric emptying rate in this treat-
ment arm at baseline. The normal baseline gastric emptying
rate may well reflect that the cohort receiving this dose was
younger and less severely ill than those who received 50 mg
of camicinal [35]. Motilin agonists are unlikely to accelerate
gastric emptying when the emptying rate at baseline is
normal or rapid [36]. Previous data in healthy volunteers
given camicinal show improvements in GE BTt½ with in-
creased doses with a plateau at the greatest dose studied
[19, 20]. The effect of erythromycin, a motilin receptor
agonist, on gastrointestinal motility is dose-dependent,
such that increasing doses may not accelerate gastric
emptying as much as low or moderate doses [36, 37].
Interpretation of these data is limited by the pretreat-
ment differences in gastric emptying, which occurred by
chance. As the investigators remained blinded and
randomization was not stratified according to baseline
gastric emptying it happened that gastric emptying was
slower in the group randomized to 50 mg camicinal.
Because the gastrokinetic effect of drugs in the critically
Table 3 3-O-methyl glucose absorption: post-dose vs. baseline comparison (excluding the n = 2 without adequate camicinal exposures)




AUC(0–240) (mmol.min/L)* 50 mg (n = 15) 28.630 71.632 2.502 (1.683, 3.719)
50 mg (n = 13)# 33.042 74.587 2.257 (1.478, 3.449)
75 mg (n = 6) 48.373 35.048 0.725 (0.387, 1.356)
Placebo (n = 12) 45.791 60.699 1.326 (0.851, 2.065)
AUC(0–60) (mmol.min/L)* 50 mg (n = 15) 2.962 11.646 3.932 (2.037, 7.588)
50 mg (n = 13)# 3.779 12.390 3.279 (1.631, 6.592)
75 mg (n = 6) 9.698 4.914 0.507 (0.179, 1.433)
Placebo (n = 12) 5.935 7.464 1.258 (0.603, 2.623)
Cmax (mmol/L)* 50 mg (n = 15) 0.1905 0.4287 2.2505 (1.5736, 3.2186)
50 mg (n = 13)# 0.2107 0.4496 2.1344 (1.4389, 3.1662)
75 mg (n = 6) 0.3530 0.2512 0.7116 (0.4042, 1.2530)
Placebo (n = 12) 0.3035 0.3824 1.2600 (0.8446, 1.8797)
3-OMG 3-O-methyl glucose, CI confidence interval, AUC area under the curve, Cmax peak 3-OMG concentration
*Log-transformed
#Two subjects administered 50 mg camicinal had low drug exposure. Analyses were performed with and without these subjects
Table 4 Acetaminophen absorption: post-dose vs. baseline comparison (excluding the n = 2 without adequate camicinal exposures)
Plasma
acetaminophen




C60 (ug/mL)* 50 mg (n = 15) 4.308 6.741 1.565 (0.962, 2.545)
50 mg (n = 13)# 4.708 7.043 1.496 (0.874, 2.560)
75 mg (n = 6) 5.398 6.315 1.170 (0.568, 2.409)
Placebo (n = 12) 6.291 6.609 1.051 (0.630, 1.751)
AUC(0–60) (ug.min/mL)
* 50 mg (n = 15) 159.31 256.93 1.61 (0.97, 2.67)
50 mg (n = 13)# 169.80 293.52 1.73 (0.99, 3.03)
75 mg (n = 6) 210.81 239.86 1.14 (0.54, 2.41)
Placebo (n = 12) 224.21 230.08 1.03 (0.60, 1.74)
CI confidence interval, AUC area under the curve
*Log-transformed
#Two subjects administered 50 mg camicinal had low drug exposure. Analyses were performed with and without these subjects
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ill depend on baseline gastric emptying [25, 36], such
that acceleration may only occur when baseline GE is
slow, it is not possible to accurately determine from the
results of this study as to whether 75 mg of camicinal
could accelerate GE more than 50 mg and further dose-
finding studies should be performed.
A further limitation is that the pretreatment gastric
emptying was more rapid in those that received placebo.
This was somewhat surprising given that patients were
eligible only if GRV was ≥200 mL. While large GRV
values are predictive of delayed gastric emptying [38, 39],
effects on gastrointestinal motility may well vary with
the severity of critical illness [40]. Indeed there is wide
variation in the threshold GRV used to define feed
intolerance, with volumes between 150 and 500 used to
identify patients with slow gastric emptying [41–43],
which limits generalizability of these data. Moreover, the
time from measurement of the GRV until the measure-
ment of gastric emptying may have been sufficient for
some patients with slow gastric emptying to recover some-
what from their illness and for gastric emptying to improve
[3]. This finding may support the practice by some groups
of treating slow GE only after a second large GRV [44].
While pharmacokinetic data are presented, accurate
assessment of half-life was not feasible in this study as
PK samples were taken only up to 24 hours, while the
half-life of the compound is about 30 hours. The short
half-life estimates reported here should, therefore, be
treated with caution. However, it appears that the elim-
ination phase of subjects with critical illness parallels
that in healthy volunteers with no evidence of changes
in elimination of camicinal in this patient population
[19]. Finally, the frequency of adverse events was similar
for both doses of camicinal and placebo, with no
treatment-related trends in clinical chemistry, vital signs,
or electrocardiogram parameters. There were no serious
adverse events assessed as related to study treatment in
this small study and hence camicinal was generally safe
and well tolerated in this critically ill population. Add-
itional studies with more patients are needed to further
characterize the safety profile of camicinal.
Conclusions
In this phase II, proof-of-principal study a single dose of
camicinal (50 mg or 75 mg) administered intragastrically
to critically ill patients with feed intolerance was well
tolerated. It was also well absorbed in almost all patients
and, when absorbed, the 50 mg dose acutely accelerated
gastric emptying resulting in improved nutrient absorp-
tion. Further clinical studies are required to determine
the effect of camicinal on the success of gastric feeding
and energy delivery in critical illness.
Key messages
 A 50 g enteral dose of camicinal, when absorbed,
accelerates gastric emptying and increases glucose
absorption and emptying in feed-intolerant critically
ill patients
 Further clinical evaluation with a larger patient
cohort is needed to further characterize the safety
profile of camicinal.
Abbreviations
3-OMG, 3-O-methyl glucose; AV, adverse event; BTt½, gastric half-emptying
time; Cmax, peak 3-OMG concentration; CVb%, coefficient of variation; EDTA,
ethylenediaminetetraacetic acid; EN, enteral nutrition; GCP, good clinical
practice; GE, gastric emptying; GEC, gastric emptying coefficient; GRV, gastric
residual volumes; ICU, intensive care unit; LC-MS/MS, liquid chromatography-
Table 5 Summary of adverse events occurring in ≥ 2 subjects
Adverse events: Camicinal
Placebo 50 mg 75 mg Total
n = 12 n = 15 n = 6 n = 33
n (%) n (%) n (%) n (%)
No. subjects with any AE 9 (75) 12 (80) 5 (83) 26 (79)
Most frequent AEs (≥2 subjects in any single group)
Gamma-glutamyltransferase increased 4 (33) 0 2 (33) 6 (18)
Oral candidiasis 0 2 (13) 1 (17) 3 (9)
Blood alkaline phosphatase increased 2 (17) 0 1 (17) 3 (9)
Decubitus ulcer 1 (8) 0 2 (33.) 3 (9)
Constipation 1 (8) 2 (13) 0 3 (9)
Vomiting 2 (17) 1 (7) 0 3 (9)
Diarrhea 2 (17) 0 0 2 (6)
Liver function test abnormal 0 2 (13) 0 2 (6)
Supraventricular tachycardia 0 2 (13) 0 2 (6)
AE adverse events
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tandem mass spectrometry; MMC, migrating motor complex; SAE, serious
adverse event; Tmax, time to peak 3-OMG concentration
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